#Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?

被引：2
作者：
Dhariwal, Randeep [1 ]
Pindoria, Nisha [1 ]
Dasgupta, Prokar [1 ]
Khan, Muhammad S. [1 ]
机构：
[1] Kings Coll London Urol, Guys Hosp, Guys & St Thomas NHS Fdn Trust, St Thomas St London, London SE1 9RT, England
来源：
BJU INTERNATIONAL | 2019年 / 123卷 / 02期
关键词：
checkpoint inhibitors; immunotherapy; metastatic urothelial carcinoma; bladder cancer; pembrolizumab; atezolizumab; CISPLATIN-INELIGIBLE PATIENTS; OPEN-LABEL; SINGLE-ARM; MULTICENTER; PEMBROLIZUMAB; CANCER; ATEZOLIZUMAB;
D O I：
10.1111/bju.14463
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：203 / 207
页数：5
相关论文
共 13 条
  • [1] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Vuky, Jacqueline
    Powles, Thomas
    Plimack, Elizabeth R.
    Hahn, Noah M.
    de Wit, Ronald
    Pang, Lei
    Savage, Mary J.
    Perini, Rodolfo F.
    Keefe, Stephen M.
    Bajorin, Dean
    Bellmunt, Joaquim
    [J]. LANCET ONCOLOGY, 2017, 18 (11) : 1483 - 1492
  • [2] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
    Balar, Arjun V.
    Galsky, Matthew D.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Loriot, Yohann
    Necchi, Andrea
    Hoffman-Censits, Jean
    Perez-Gracia, Jose Luis
    Dawson, Nancy A.
    van der Heijden, Michiel S.
    Dreicer, Robert
    Srinivas, Sandy
    Retz, Margitta M.
    Joseph, Richard W.
    Drakaki, Alexandra
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Duran, Ignacio
    Shaffer, David R.
    Eigl, Bernhard J.
    Grivas, Petros D.
    Yu, Evan Y.
    Li, Shi
    Kadel, Edward E., III
    Boyd, Zachary
    Bourgon, Richard
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Thastrom, AnnChristine
    Abidoye, Oyewale O.
    Fine, Gregg D.
    Bajorin, Dean F.
    [J]. LANCET, 2017, 389 (10064) : 67 - 76
  • [3] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
  • [4] A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
    Bellmunt, Joaquin
    Powles, Thomas
    Vogelzang, Nicholas J.
    [J]. CANCER TREATMENT REVIEWS, 2017, 54 : 58 - 67
  • [5] Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study
    Galsky, M. D.
    Retz, M.
    Siefker-Radtke, A. O.
    Baron, A.
    Necchi, A.
    Bedke, J.
    Plimack, E. R.
    Vaena, D.
    Grimm, M-O.
    Bracarda, S.
    Arranz Arija, J.
    Pal, S. K.
    Ohyama, C.
    Saci, A.
    Lambert, A.
    Krishnan, S.
    Azrilevich, A.
    Sharma, P.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes
    Galsky, Matthew D.
    Wang, Huan
    Hahn, Noah M.
    Twardowski, Przemyslaw
    Pal, Sumanta K.
    Albany, Costantine
    Fleming, Mark T.
    Starodub, Alexander
    Hauke, Ralph J.
    Yu, Menggang
    Zhao, Qianqian
    Sonpavde, Guru
    Donovan, Michael J.
    Patel, Vaibhav G.
    Sfakianos, John P.
    Domingo-Domenech, Josep
    Oh, William K.
    Akers, Nicholas
    Losic, Bojan
    Gnjatic, Sacha
    Schadt, Eric E.
    Chen, Rong
    Kim-Schulze, Seunghee
    Bhardwaj, Nina
    Uzilov, Andrew V.
    [J]. EUROPEAN UROLOGY, 2018, 73 (05) : 751 - 759
  • [7] Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) plus FOLFOX in metastatic pancreatic adenocarcinoma (PDAC).
    Hecht, J. Randolph
    Falchook, Gerald Steven
    Patel, Manish R.
    Aljumaily, Raid
    Infante, Jeffrey R.
    Naing, Aung
    Wong, Deborah Jean Lee
    Autio, Karen A.
    Ratti, Navneet
    Wainberg, Zev A.
    Bendel, Johanna C.
    Pant, Shubham
    Brown, Gail Linda
    Van Vlasselaer, Peter
    Oft, Martin
    Papadopoulos, Kyriakos P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Immune checkpoint inhibitors for metastatic bladder cancer
    Massari, Francesco
    Di Nunno, Vincenzo
    Cubelli, Marta
    Santoni, Matteo
    Fiorentino, Michelangelo
    Montironi, Rodolfo
    Cheng, Liang
    Lopez-Beltran, Anto
    Battelli, Nicola
    Ardizzoni, Andrea
    [J]. CANCER TREATMENT REVIEWS, 2018, 64 : 11 - 20
  • [9] Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
    Plimack, Elizabeth R.
    Bellmunt, Joaquim
    Gupta, Shilpa
    Berger, Raanan
    Chow, Laura Q. M.
    Juco, Jonathan
    Lunceford, Jared
    Saraf, Sanatan
    Perini, Rodolfo F.
    O'Donnell, Peter H.
    [J]. LANCET ONCOLOGY, 2017, 18 (02) : 212 - 220
  • [10] Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
    Powles, Thomas
    Duran, Ignacio
    van der Heijden, Michiel S.
    Loriot, Yohann
    Vogelzang, Nicholas J.
    De Giorgi, Ugo
    Oudard, Stephane
    Retz, Margitta M.
    Castellano, Daniel
    Bamias, Aristotelis
    Flechon, Aude
    Gravis, Gwenaelle
    Hussain, Syed
    Takano, Toshimi
    Leng, Ning
    Kadel, Edward E., III
    Banchereau, Romain
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Cui, Na
    Shen, Xiaodong
    Derleth, Christina L.
    Green, Marjorie C.
    Ravaud, Alain
    [J]. LANCET, 2018, 391 (10122) : 748 - 757
12